Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Wells Fargo & Company from $21.00 to $30.00. They now have an "overweight" rating on the stock.
Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Mizuho from $24.00 to $30.00. They now have an "outperform" rating on the stock.
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.